Skip to main content

Advertisement

Table 1 Characteristics of the included trials in this meta-analysis

From: Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis

Author Year Geographic Locale Study Design Regimen Sample size Duration, weeks
Chen [15] 2017 China,Sichuan province RCT TDF:300 mg/d; LAM:100 mg/d 100 48
Chen [16] 2013 China,Jiangsu province RCT TDF:300 mg/d; LAM:100 mg/d 60 72
Gao [17] 2016 China,Jilin province RCT TDF:300 mg/d; LAM:100 mg/d 70 48
He [18] 2015 China,Guangdong province RCT TDF:300 mg/d; LAM:100 mg/d 50 48
Jain [12] 2006 the USA Retrospective cohort TDF:300 mg/d; LAM:100 mg/d 25 48
Li [13] 2016 China,multi-centers Retrospective cohort TDF:300 mg/d; LAM:100 mg/d 151 48
Liu [19] 2017 China,Shaanxi province RCT TDF:300 mg/d; LAM:100 mg/d 120 72
Luo [20] 2016 China,Jiangxi province RCT TDF:300 mg/d; LAM:100 mg/d 20 24
Min Zhou [21] 2016 China,Jiangxi province RCT TDF:300 mg/d; LAM:100 mg/d 90 48
Wang [14] 2016 China,Guangxi province RCT TDF:300 mg/d; LAM:100 mg/d 31 11~ 24
Yan Zhou [22] 2016 China,Henan province RCT TDF:300 mg/d; LAM:100 mg/d 110 48
  1. Sample size and duration were expressed in mean